HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Archive

All News

Every briefing, headline, and filing we've published, newest first.

J&J, chasing $100B year, sports immunology ‘dual powerhouse’ of Tremfya and new launch Icotyde
MoneyFiercePharma ↗
Protagonist Therapeutics-partnered Icotyde has the potential to become one of Johnson & Johnson's "largest…
Apr 17, 2026
Johnson & Johnson hands back failed eye disease gene therapy to MeiraGTx
PipelineFierceBiotech ↗
After its bet on a rare eye disease gene therapy ended in a phase 3 fail, Johnson & Johnson is returning t…
Apr 17, 2026
Teva scores in appeal as court revives $177M verdict against Lilly in migraine patent spat
PolicyFiercePharma ↗
The legal back-and-forth over migraine meds from Teva and Eli Lilly has resurfaced, with Teva gaining favor on…
Apr 17, 2026
UCB Buys Neurona for $650M, Bets on Regenerative Medicine and Epilepsy Cell Therapy
DealsBriefing
UCB’s $650M-plus purchase of Neurona Therapeutics signals a move beyond small molecules into regenerative neur…
Apr 17, 2026
Storm’s $56M Raise Puts RNA Editing on Venture Capital’s Radar
Money
Backed by Pfizer Ventures and M Ventures, Storm Therapeutics’ $56M Series C funds a Phase 2 sarcoma trial and …
Apr 17, 2026
Gilead’s Yeztugo Access Pledge Meets Resistance from MSF and Global Health Advocates
Policy
Gilead plans to supply Yeztugo to 3M people through 2028 via Global Fund partnerships, but MSF calls the scale…
Apr 17, 2026
Novo Nordisk Bets on OpenAI to Accelerate Drug Development
DealsBriefing
Novo Nordisk unveiled a global AI collaboration with OpenAI, extending from drug discovery to manufacturing as…
Apr 17, 2026
Aligos Monetizes China Rights to HBV Drug in $445M Pact with Amoytop
Deals
Aligos sells Greater China rights to its phase 2 HBV drug for $25M upfront and up to $420M in milestones, as A…
Apr 17, 2026
20,342 Patients, Minimal Impact: Cochrane’s Meta-Analysis Shakes Alzheimer’s Pipeline Economics
Pipeline
A 17-trial review of 20,342 subjects found “absent or trivial” benefit from anti-amyloid drugs like Leqembi an…
Apr 17, 2026
Kailera’s $625M IPO Reopens the Biotech Window
MoneyBriefing
The Waltham-based obesity biotech priced at the top of its range, surpassing Moderna’s 2018 record and signali…
Apr 17, 2026
Lilly’s Foundayo Scores a Cardiovascular Win, Easing FDA Concerns Ahead of Diabetes Filing
Pipeline
Lilly’s oral GLP-1 Foundayo showed non-inferiority to insulin glargine in Type 2 diabetes, addressing FDA safe…
Apr 17, 2026
FDA’s Peptide Pivot Shows Politics Reordering Compounding Policy
Policy
Reclassification of 12 unapproved peptides ahead of a July advisory meeting marks a sharp policy turn, raising…
Apr 17, 2026
STAT+: A pancreatic cancer expert on why Revolution Medicines’ study could ‘open up a new era’ of treatment
PipelineSTAT News ↗
"I do think it's a revolution," said Paul Oberstein of NYU Langone's Perlmutter Cancer Center.…
Apr 17, 2026
#AACR26 preview: Revolution Medicines, the RAS bonanza and China ADC standouts
The WeekEndpoints News ↗
The oncology field is buzzing after a landmark readout from Revolution Medicines, known colloquially as RevMed…
Apr 17, 2026
STAT+: FDA eyes expanding testosterone therapy for libido
PolicySTAT News ↗
New research questions GLP-1's purpose, a pancreatic cancer breakthrough, and more biotech news from The Reado…
Apr 17, 2026
Biovac gets $108M backing for vaccine factory in South Africa
DealsEndpoints News ↗
Biovac’s new vaccine factory in Cape Town, which is expected to make up to 400 million vaccines per year, has …
Apr 17, 2026
The deadly consequences of ICE detention
The WeekSTAT News ↗
New research challenges what we know about GLP-1s, vaccine skepticism, and more health news from Morning Round…
Apr 17, 2026
Roche’s DAC investment; Big Pharma’s lavish CEO bumps
MoneyPharmaVoice ↗
Roche is investing in new cancer-fighting technology, and some of Big Pharma's CEOs notched some noteworthy pa…
Apr 17, 2026
Can an LSD candidate do for anxiety what Spravato did for depression?
PipelinePharmaVoice ↗
Definium Therapeutics is expecting late-stage data for two anxiety trials in the coming months, teeing up a po…
Apr 17, 2026
Lilly’s tirzepatide sheds lean muscle harder than Novo’s semaglutide, study suggests
The WeekEndpoints News ↗
While Eli Lilly’s tirzepatide helps patients drop more weight than Novo Nordisk’s semaglutide, this might come…
Apr 17, 2026
5 notable pharma CEO pay hikes in 2025
The WeekBioPharma Dive ↗
Several of pharma’s top leaders scored large pay bumps last year, including two new chiefs who joined th…
Apr 17, 2026
The innovators working to make in vivo cell therapy a reality
The WeekPharmaceutical Technology ↗
As in vivo cell therapies enter clinical trials, suppliers tackle the technical and logistical barriers to com…
Apr 17, 2026
Daiichi Sankyo and Interna partner for MNM-targeted delivery solutions
DealsPharmaceutical Technology ↗
Daiichi Sankyo has partnered with Interna Therapeutics to develop targeted delivery solutions based on molecul…
Apr 17, 2026
STAT+: Cell therapy primed liver transplant patients to avoid organ rejection, small study shows
PipelineSTAT News ↗
A few transplant patients in a small study were able to stop using immunosuppressive drugs, thanks to pre-tran…
Apr 17, 2026
← Newer Page 15 Older →
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.